pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights
July 2020 Highlights:
- 6 products completed CADTH review
- 6 products initiated pCPA negotiations
- 7 negotiations were completed with an LOI
- 0 negotiations were closed without an LOI
- 0 files were closed without negotiation
Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start but those that start are being negotiated more quickly. There also appears to be a stabilization of activity across metrics as detailed below.
Files Under pCPA Consideration:
CADTH issued 6 new recommendations in July (24 files as of July 31).
|Ischemic events in statin-treated patients||HLS Theraputics||CDR||July 16|
|Ulcerative Colitis||Janssen||CDR||July 16|
|Tecentriq & Avastin
(atezolizumab & bevacizumab)
|Non-Squamous Non-Small Cell Lung Cancer||Hoffman-La Roche||pCODR||July 20|
|Secondary progressive multiple sclerosis||Novartis||CDR||July 21|
|Vocabria and Cabenuva
(cabotegravir sodium cabotegravir-rilpivirine)
|HIV-1 Infection||ViiV Heaalthcare||CDR||July 22|
* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)
The Volume of files Under Consideration has stabilized over the last 3 months staying around the 23-24 mark. Pre-COVID, these numbers were consistently ≤ 11. The average time Under Consideration continues to climb, but still remains less than 3 months.
The pCPA initiated 6 new negotiations in July (27 active negotiations as of July 31, 2020)
|Multiple Myeloma||Janssen||Other||July 10||N/A|
|Peripheral T-Cell Lymphoma||Seattle Genetics||pCODR||July 3||14|
|Metastatic Gastric Cancer||Taiho||pCODR||July 7||90|
|Atopic Dermatitis||Sanofi Genzyme||CDR||July 28||97|
(iron (iii) isomaltoside 1000)
|Iron Deficiency Anemia||Pharmacosmos A/S||CDR||July 21||118|
|Major Depressive Disorder||Lundbeck||CDR||July 6||145|
* TTI = Time to Initiate in calendar days
The volume of active files continues to be lower than seen pre-COVID, corresponding with the higher number of files Under Consideration. However, we see a stabilization in the numbers from May – July 2020 perhaps signalling an equilibrium in activity.
Of the 6 files that initiated negotiations, they were evenly split between oncology and non-oncology files. Most were under consideration for 3-5 months before being initiated with the exception of Adcetris for Peripheral T-Cell lymphoma which was initiated within 2 weeks of the Notification to Implement date.
The pCPA completed 7 negotiations with a Letter of Intent (LOI) in July 2020.
|Advanced or metastatic breast cancer||Novartis||July 14||22|
|For the emergency treatment of severe acute allergic reactions (anaphylaxis)||Kaleo||July 22||61|
|Kisqali with fulvestrant
|Advanced or metastatic breast cancer||Novartis||July 14||64|
|Febrile neutropenia in non-myeloid malignancies||Sandoz||July 22||86|
|Prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients||Paladin Labs||July 30||136|
(lutetium 177 dotatate)
|Gastroenteropancreatic neuroendocrine tumors||Advanced Accelerator Applications||July 29||154|
|Ulcerative Colitis||Pfizer||July 24||385|
* TTN = Time to Negotiate in calendar days
The average duration of negotiation for currently active files time has dropped since March, with the current average sitting at 4 months compared to 5.7 months in February.
The number of protracted negotiations (active more than 12 months) has decreased and is very low (from 5 to only 1) while the opposite trend is occurring with the number of files Under Consideration for extended periods (greater than 6 months) which we see increasing (from 0 to 4).
Total number of adjudicated files appears to be trending back towards numbers generally seen pre-COVID.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.